Last updated: December 6, 2024
Sponsor: The University of Texas Health Science Center, Houston
Overall Status: Active - Recruiting
Phase
N/A
Condition
Circulation Disorders
Vascular Diseases
Dizzy/fainting Spells
Treatment
Group 1: LEE
Clinical Study ID
NCT06513169
HSC-MS-22-0145
Ages 18-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
American Society of Anesthesiologists (ASA)3 or lower
Patients requiring general anesthesia
Exclusion
Exclusion Criteria:
Allergic reaction to drugs commonly used for general anesthesia including fentanyl,midazolam, propofol, ephedrine and phenylephrine
Pregnant women
Requiring rapid sequence induction
Prisoners
Patient refusal
Emergency Surgery
Study Design
Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Group 1: LEE
Phase:
Study Start date:
August 12, 2024
Estimated Completion Date:
December 31, 2024
Connect with a study center
The University of Texas Health Science Center at Houston
Houston, Texas 77030
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.